Wechselwirkungen · Ilaris
Ilaris 150 mg/ml solution for injection Ilaris 150 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 9
HOS-122014 · Präparat HOS-095465
The expression of hepatic CYP450 enzymes may be suppressed by the cytokines that stimulate chronic inflammation, such as interleukin-1 beta (IL-1 beta). Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as canakinumab, is introduced. This is clinically relevant for CYP450 substrates with a narrow therapeutic index where the dose is individually adjusted. On initiation of canakinumab in patients being treated with this type of medicinal product, it is recommended that therapeutic monitoring of the effect or of the active substance concentration is performed and the individual dose of the medicinal product adjusted as necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-05T15:45:00Z · SHA-256 dab74bfeca2bcb286b07151a7bc327aaa62f3eb7f0ded500ec062f70f9bdfb5a · Passage 2ce03e06497f2da4f9c2dd61392385d1a25082f43f7a390eef0d17216ba598e2 · Zeichen 371–1041 im Abschnitt